MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:59:03 13/01/2026 GMT			5-day change	1st Jan Change
5.685 ^USD	-1.47%		+0.98%	+0.09%

01-08	MannKind provides business updates and 2026 growth drivers	RE
12-23	MannKind Says FDA Approves Furoscix Autoinjector Use for Pediatric Patients With Fluid Retention	MT

MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

Published on 11/05/2025 at 03:51 pm GMT

S&P Capital IQ

MannKind Corporation

-1.47%

MannKind Corporation reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported revenue was USD 82.13 million compared to USD 70.08 million a year ago. Net income was USD 7.99 million compared to USD 11.55 million a year ago. Basic earnings per share from continuing operations was USD 0.03 compared to USD 0.04 a year ago. Diluted earnings per share from continuing operations was USD 0.03 compared to USD 0.04 a year ago.
For the nine months, revenue was USD 237.01 million compared to USD 208.73 million a year ago. Net income was USD 21.81 million compared to USD 20.17 million a year ago. Basic earnings per share from continuing operations was USD 0.07 compared to USD 0.07 a year ago. Diluted earnings per share from continuing operations was USD 0.07 compared to USD 0.07 a year ago.

Latest news about MannKind Corporation

01-08	MannKind provides business updates and 2026 growth drivers	RE
12-23	MannKind Says FDA Approves Furoscix Autoinjector Use for Pediatric Patients With Fluid Retention	MT
12-23	MannKind Corporation Shares FUROSCIX®? Business Updates	CI
12-18	Cartesian Therapeutics, Inc. Announces the Appointment of Adrian Bot to Board of Directors and Member of the Science and Technology Committee	CI
12-01	MannKind Seeks FDA Approval for ReadyFlow Autoinjector	MT
12-01	MannKind announces U.S. FDA accepts for review its supplemental new drug application (sNDA) of Furoscix Readyflow(TM) autoinjector	RE
12-01	MannKind Corporation Announces U.S. FDA Accepts for Review its Supplemental New Drug Application of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Kidney Disease	CI
11-11	RBC Lowers Price Target on MannKind to $7.50 From $8, Keeps Outperform Rating	MT
11-11	Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating	MT
11-10	MannKind Corporation Announces Discontinuing its Phase 3 Clinical Trial Evaluating Nebulized Inhalation Suspension of Clofazimine	CI
11-10	MannKind Corporation - Special Call
11-10	MannKind Discontinues Phase 3 Trial of Nebulized Clofazimine to Treat Lung Disease	MT
11-05	MannKind Corporation, Q3 2025 Earnings Call, Nov 05, 2025
11-05	MannKind Shares Rise After Q3 Beat	MT
11-05	MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	MannKind's Q3 Non-GAAP Net Income, Revenue Rise	MT
11-05	Biopharma MannKind's Q3 revenue up 17%	RE
11-05	Earnings Flash (MNKD) MannKind Corporation Reports Q3 Revenue $82.1M, vs. FactSet Est of $80.2M	MT
11-05	Earnings Flash (MNKD) MannKind Corporation Posts Q3 Adjusted EPS $0.07 per Share, vs. FactSet Est of $0.03	MT
13/10/25	Mannkind Corporation Announces U.S. Fda Accepts for Review Its Supplemental Biologics License Application for Inhaled Insulin in Children and Adolescents Aged 4-17 Years Living with Diabetes	CI
13/10/25	MannKind's Supplemental BLA for Diabetes Treatment Afrezza Facing 'Limited Regulatory Risk,' Wedbush Says	MT
13/10/25	MannKind's Biologics License Application for Diabetes Treatment Afrezza Accepted by FDA	MT
13/10/25	MannKind announces US FDA accepts for review its sBLA for inhaled insulin	RE
07/10/25	MannKind Corporation completed the acquisition of scPharmaceuticals Inc..	CI
07/10/25	MannKind Completes Acquisition of scPharmaceuticals	MT

Chart MannKind Corporation

Duration

Period

MNKD: Dynamic Chart

Company Profile

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Employees

405

Sector

Biotechnology & Medical Research

Calendar

03-02 - Q4 2025 Earnings Release (Projected)

More about the company